Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06117306 · ClinicalTrials.gov registry record · Phase 3
MDMA-assisted Massed Prolonged Exposure for PTSD
A Phase 3 study of Post Traumatic Stress Disorder, sponsored by Healing Breakthrough.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06117306 is a Phase 3 study of Post Traumatic Stress Disorder that is actively recruiting participants, run by Healing Breakthrough. The registered enrollment target is 20 participants, below the 1,117-participant average among 144 other Post Traumatic Stress Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06117306, a Phase 3 study of Post Traumatic Stress Disorder, is actively recruiting participants, sponsored by Healing Breakthrough.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall objective of this study is to pilot the VASDHS-adapted Emory MDMA-PE Protocol (aE-MDMA-PE) and assess the effect on clinician-rated PTSD symptoms in veterans who receive different doses of MDMA.
Conditions Studied
Interventions
- BEHAVIORAL Prolonged Exposure
- DRUG 3,4 Methylenedioxymethamphetamine
Study Locations (1)
California
- VA San Diego Healthcare System, San Diego, CA - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-10-25 |
| Est. Completion | 2026-01-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06117306
The ClinicalTrials.gov registry entry for NCT06117306 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,117-participant average among 144 other Post Traumatic Stress Disorder trials with a reported enrollment target (98% lower). The listed sponsor is Healing Breakthrough, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 2 interventions - of which Prolonged Exposure is the first listed.
NCT06117306 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06117306 about?
NCT06117306 is a clinical study titled "MDMA-assisted Massed Prolonged Exposure for PTSD". The overall objective of this study is to pilot the VASDHS-adapted Emory MDMA-PE Protocol (aE-MDMA-PE) and assess the effect on clinician-rated PTSD symptoms in veterans who receive different doses of MDMA.
What is the current status of trial NCT06117306?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2024-10-25. Estimated completion is 2026-01-01.
What conditions does trial NCT06117306 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder.
What interventions are being tested in trial NCT06117306?
The interventions under investigation include: Prolonged Exposure (BEHAVIORAL), 3,4 Methylenedioxymethamphetamine (DRUG).
Who is sponsoring clinical trial NCT06117306?
This trial is sponsored by Healing Breakthrough, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06117306 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
RECRUITING · Phase 3
-
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
RECRUITING · Phase 3
-
Frontline Clinician Psilocybin Study
COMPLETED · Phase 3
-
Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD)
COMPLETED · Phase 3
-
Comparison of Videoconference and Face-to-Face Delivery of Cognitive Processing Therapy for Posttraumatic Stress Disorder
COMPLETED · Phase 3
-
Maximizing Treatment Outcome in Post-Traumatic Stress Disorder (PTSD)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.